#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Subdural haematoma Cardiac arrest Rhabdomyosarcoma recurrent Cerebral haemorrhage Glioblastoma multiforme Gastrointestinal neuroendocrine tumour Exudative retinopathy Nodal marginal zone B-cell lymphoma Leber's congenital amaurosis Mucopolysaccharidosis I Monogenic diabetes HER2 gene amplification Pancreatic carcinoma metastatic Immune-mediated renal disorder Cholangiosarcoma More trials…

    Learn about Rare Diseases

    Brain stem glioma – Diagnostics Lymphatic malformation – Basic Information Leiomyosarcoma recurrent – Trials in Disease Hereditary ataxia – Basic Information Urea cycle disorder – Trials in Disease Myxofibrosarcoma – Diagnostics Haemophilia B without inhibitors Myelodysplastic syndrome – Treatment Ehlers-Danlos syndrome – Life with Disease Brain stem glioma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ficlatuzumab Goserelin Bhv-7000 Nivolumab Bedaquiline Entrectinib Garadacimab OMTX705 Diroximel Fumarate Ciclosporin A RO7837195 Dacomitinib Rbp030.2 Nystatin Ezetimibe Iberdomide ANTI-GD2-800CW IPN01195 Feladilimab Rizolipase More therapies…

    Learn about Your Condition

    Rectal cancer recurrent Peripheral ischaemia Propionic acidaemia Persistent depressive disorder Rhabdoid tumour Skin angiosarcoma Pemphigus Narcolepsy Bacterial prostatitis Acromegaly Sciatica Lip and/or oral cavity cancer Intracranial calcification Subarachnoid haemorrhage Dengue fever More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Clintrial s.r.o.

Clintrial s.r.o.

Pocernicka 1427/16, Strasnice, Prague, 100 00, Czechia

Want to learn more about this study or check if you can participate? Contact us.

  • Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks

    Recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
    Austria Czechia Denmark France Germany Italy +3

  • Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

    Recruiting

    3 1 1
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    • Povorcitinib
    Austria Belgium Bulgaria Czechia Denmark France +7

  • Study on ITI-1284 for Patients with Generalized Anxiety Disorder Who Did Not Respond Well to Previous Treatments

    Recruiting

    2 1
    Investigated Drugs:
    • Iti-1284
    Bulgaria Czechia Finland Poland Slovakia

  • Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Adults with Moderate to Severe Atopic Dermatitis (Phase 2 Study)

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Bulgaria Czechia Germany Italy Poland Spain

  • A Phase 2b Study Evaluating the Efficacy and Safety of ENV-294 in Adults with Moderate-to-Severe Atopic Dermatitis

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Bulgaria Czechia Germany Poland Spain

  • A study to evaluate the effectiveness and safety of JNJ-88545223 in people with active psoriatic arthritis

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Czechia Germany Hungary Poland Spain

  • A study of azetukalner compared to placebo for adults with moderate-to-severe major depressive disorder

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Major depression
    Investigated Drugs:
    • Azetukalner
    Czechia Finland Germany Poland Romania Slovakia +1

  • Study to evaluate ATI-045 injection compared to placebo in adults with moderate to severe atopic dermatitis

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST THYMIC STROMAL LYMPHOPOIETIN
    Czechia Germany Poland

  • Study of IMG-007 injection to treat moderate to severe atopic dermatitis in adults

    Not yet recruiting

    2 1
    Investigated Drugs:
    • Img-007
    Czechia Germany Hungary Poland Spain

  • Safety and effectiveness study of PN6047 HCl in adults with peripheral neuropathic pain and mechanical allodynia

    Not yet recruiting

    2 1
    Czechia Poland Spain
Previous Page
1 2 3 4 5 … 8
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!